Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 5/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3162522 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5873428 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3154863 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13365113 | 0.88 | SLC6A4 (0.79) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3829085 | 0.86 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13979133 | 0.86 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL527574 | 0.86 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1086468 | 0.86 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL16108247 | 0.86 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7086274 | 0.86 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060094759-A1 | Novel piperdine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2006-05-04 | — | — | US | claimed |
| JP-2006507363-A | — | — | 2006-03-02 | — | — | JP | claimed |
| EP-1560813-A1 | NOVEL PIPERIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NeuroSearch A/S (DK) | 2005-08-10 | — | — | EP | claimed |
| WO-2004039778-A1 | NOVEL PIPERIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2004-05-13 | — | — | WO | claimed |
| EP-1560813-B1 | NOVEL PIPERIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH AS (DK) | 2010-03-17 | — | — | EP | disclosed |
| US-7560562-B2 | Piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2009-07-14 | — | — | US | disclosed |
| US-20060094759-A1 | Novel piperdine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2006-05-04 | — | — | US | disclosed |
| EP-1560813-A1 | NOVEL PIPERIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NeuroSearch A/S (DK) | 2005-08-10 | — | — | EP | disclosed |
| WO-2004039778-A1 | NOVEL PIPERIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094759-A1 | Novel piperdine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | SLC18A2, SLC6A2, SLC18A3 | SLC6A2 2/4885SLC6A4 5/4885SLC6A3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.